Протеомный штрих-код плазмы крови для диагностики злокачественных опухолей
Диссертация
Протеомный штрих-код плазмы крови, регистрируемый посредством МАЬВ1(8ЕЬ01)-ТОР-масс-спектрометрии, обеспечивает достоверное разграничение образцов от пациентов с раком яичника и от контрольных субъектов с точностью диагностики, равной 90%, что превосходит точность, обеспечиваемую общепринятым маркером С А-125. Компоненты штрих-кода, вносящие вклад в диагностику, представляют собой высококопийные… Читать ещё >
Список литературы
- Арчаков А.И. Что после геномики? Протеомика // Вопр. мед. химии. 2000. Т.46. С.335−343.
- Говорун В.М., Арчаков А. И. Протеомные технологии в современной биомедицинской науке // Биохимия. 2002. Т.67. С. 1341−1359.
- Говорун В.М., Иванов В. Т. Протеомика и пептидомика в фундаментальных и прикладных медицинских исследованиях //Биоорганическая химия. 2011. Т.37(2).С. 199−215.
- Громов П.С., Целис Х. Э. От геномики к протеомике // Молекулярная биология. 2000. Т.34. С.597−611.
- Иванов A.C., Згода В. Г., Арчаков А. И. Технологии белковой интерактомики // Биоорганическая химия. 2011. Т.37(1).С.8−21.
- Пономаренко Е.А., Ильгисонис Е. В., Лисица A.B. Технологии знаний в протеомике // Биоорганическая химия. 2011.Т.37(2). С. 190−198.
- Пономаренко Е.А., Лисица A.B., Ильгисонис Е. В., Арчаков А. И. Конструирование семантических сетей белков с использованием PubMed/Medline // Молекулярная биология. 2010. Т.44(1). С. 152−161.
- Шишкин С.С., Ковалев Л. И., Ковалева М. А. Протеомные исследования мышечных белков человека и некоторых других позвоночных //Биохимия. 2004. Т.69(11). С. 1574−1589.
- Ahmed N. Oliva K.T., Barker G., Hoffmann P., Reeve S., Smith I.A., Quinn M.A., and Rice G.E. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer // Proteomics. 2005. V.5(17). P.4625−4636.
- Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins // Molecular & cellular proteomics. 2006. V.5(4). P.573−588.
- Anderson N.L., Hofmann J. P., Gemmell A., and Taylor J. Global approaches to quantitative analysis of gene-expression patterns observed by use of two-dimensional gel electrophoresis // Clinical chemistry. 1984. V.30(12 Pt 1). P. 2031−2036.
- Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects // Molecular & cellular proteomics. 2002. V. 1(11). P.845−867.
- Archakov A.I., Ivanov Y.D., Lisitsa A. V., and Zgoda V.G. AFM fishing nanotechnology is the way to reverse the Avogadro number in proteomics // Proteomics. 2007. V.7(l). P.4−9.
- Archakov A., Aseev A., Bykov V., Grigoriev A., Govorun V., Ivanov V., Khlunov A., et al. Gene-centric view on the human proteome project: the example of the Russian roadmap for chromosome 18//Proteomics. 2011. V. 11(10). P. 1853−1856.
- Baumann S., Ceglarek U., Fiedler G.M., Lembcke J., Leichtle A., and Thiery J.
- Standardized approach to proteome profiling of human serum based on magnetic bead211separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry// Clinical chemistry. 2005. V.51(6). P.973−980.
- Bernstein L.H., and Ingenbleek Y. Transthyretin: its response to malnutrition and stress injury. clinical usefulness and economic implications // Clinical Chemistry and Laboratory Medicine. 2002. V.40(12). P. 1344−1348.
- Bignell G.R., Greenman C.D., Davies H., Butler A. P., Edkins S., Andrews J.M., Buck G., et al. Signatures of mutation and selection in the cancer genome // Nature. 2010. V.463(7283). P.893−898.
- Bischof P., Galfetti M.A., Seydoux J., von Hospenthal J.Y., and Campana A. Peripheral CA 125 levels in patients with uterine fibroids // Human reproduction (Oxford, England). 1992. V.7(l). P.35−38.
- Blum H., Beier H., and Gross H.J. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels// Electrophoresis. 1987. V.8. P.93−99.
- Adreas B., Ruschhaupt M., Kuner R., and Tresch A. Classification across gene expression microarray studies // BMC bioinformatics. 2009. V. 10. P.453.
- Burger D., and Dayer J.M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation // Autoimmun Rev. 2002. V. 1(1−2). P. 111−117.
- Casl M. T, Surina B., Glojnaric-Spasic I., Pape E., Jagarinec N., and Kranjcevic S. Serum amyloid A protein in patients with acute myocardial infarction // Annals of clinical biochemistry. 1995. V.32(Pt 2). P. 196−200.
- ChanD.C., Chen C .J., Chu H.C., Chang W.K., Yu J.C., Chen Y.J., Wen L.L., et al. Evaluation of serum amyloid A as a biomarker for gastric cancer // Ann Surg Oncol. 2007. V. 14(1). P.84−93.
- Chen C.B., Su Y.C., Huang T.T., Ho H.C., Chang Y.T., Tung Y.T., and Lee W.C. Differentially expressed serum haptoglobin alpha chain isoforms with potentialapplication for diagnosis of head and neck cancer // Clin Chim Acta. 2008. V.398(l-2). P.48−52.
- Chen Y., Lim B.K., Peh S.C., Abdul-Rahman P. S., and Hashim O.H. Profiling of serum and tissue high abundance acute-phase proteins of patients with epithelial and germ line ovarian carcinoma // Proteome Science. 2008. V.6. P. 20.
- Cheng A.J., Chen L.C., Chien K.Y., Chen Y.J., Chang J.T., Wang H.M., Liao C.T., and Chen I.H. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology // Clin Chem. 2005. V.51(12). P. 2236−2244.
- Cocco E., Bellone S., El-Sahwi K., Cargnelutti M., Casagrande F., Buza N., Tavassoli F.A., et al. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer // British journal of cancer. 2009. V. 101(2). P.335−341.
- Coussens L.M., and Werb Z. Inflammation and cancer // Nature. 2002. V.420(6917). P.860−867.
- Dai S., Wang X., Liu L., Liu J., Wu S., Huang L., Xiao X., and He D. Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum // Sci China C Life Sci. 2007. V.50(3). P.305−311.
- DeClerck Y.A., Mercurio A.M., Stack M.S.,. Chapman H. A, Zutter M.M., Muschel R.J., Raz A., et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section // Am J Pathol. 2004. V. 164(4). P. 1131−1139.
- Devakonda A., George L., Raoof S., Esan A., Saleh A., and Bernstein L.H. Transthyretin as a marker to predict outcome in critically ill patients // Clin Biochem. 2008. V.41(14−15).P. 1126−1130.
- Dhainaut J.F., Marin N., Mignon A., and Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes // Crit Care Med. 2001. V. 29(7 Suppl). P. S42−7.
- Diamandis E. P. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? // Clin Chem. 2003. V.49(8). P. 1272−1275.
- Diamandis E. P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems // Journal of the National Cancer Institute. 2004. V.96(5). P.353−356.
- Doherty S. D, Ni X., Doherty C.B., Jones D., Zhao X., Owen L. B, and Duvic M. Abnormal expression of interleukin-23 in mycosis fungoides/Sezary syndrome lesions // Archives of dermatological research. 2006. V. 298(7). P.353−356.
- Duche J.C., Urien S., Simon N., Malaurie E., Monnet I., and Barre J. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer // Clinical biochemistry. 2000. V.33(3). P. 197−202.
- Echan L.A., Tang H.Y., Ali-Khan N., Lee R., and Speicher D.W. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma // Proteomics. 2005. V.5(13). P.3292−3303.
- Edgell T., Martin-Roussety G., Barker G., Autelitano D.J., Allen D., Grant P., and Rice G.E. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer // J Cancer Res Clin Oncol. 2010. V. 136(7). P. 1079−1088.
- El-Akawi Z.J., Al-Hindawi F.K., and Bashir N.A. Alpha-1 antitrypsin (alphal-AT) plasma levels in lung, prostate and breast cancer patients // Neuro Endocrinol Lett. 2008. V. 29(4). P.482−484.
- Escher N., Kaatz M., Melle C., Hipler C., Ziemer M., Driesch D., Wollina U., and von Eggeling F. Posttranslational modifications of transthyretin are serum markers in patients with mycosis fiingoides // Neoplasia. 2007. V.9(3). P. 254−259.
- Etzioni R., Urban N., Ramsey S., Mcintosh M., Schwartz S., Reid B., Radich J., Anderson G., and Hartwell L. The case for early detection// Nat Rev Cancer. 2003. V.3(4). P. 243−252.
- Faca V., Krasnoselsky A., and Hanash S. Innovative proteomic approaches for cancer biomarker discovery // Biotechniques. 2007. V.43(3). P. 279,281−283,285.
- Fernandez-Miranda C., Mateo S., Gonzalez-Gomez C., and Ballestin C. Systemic amyloidosis and ovarian carcinoma // Postgraduate medical journal. 1994. V.70(825). P.505−506.
- Findeisen P., Zapatka M., Peccerella T., Matzk H., Neumaier M., Schadendorf D., and Ugurel S. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.// Journal of clinical oncology. 2009. V. 27(13). P. 2199−2208.
- Finkel T., Serrano M., and Blasco M.A. The common biology of cancer and ageing // Nature. 2007. V.448(7155). P.767−774.
- Fu Q., Bovenkamp D.E., and Van Eyk J.E. A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis // Methods Mol Biol. 2007. V.357. P.365−371.
- Fung E.T., Yip T.T., Lomas L., Wang Z., Yip C., Meng X.Y., Lin S., et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays // Int J Cancer. 2005. V. 115(5). P.783−789.
- Gasque P. Complement: a unique innate immune sensor for danger signals." Mol Immunol. 2004. V.41(ll). P. 1089−1098.
- Geho D.H., Liotta L.A., Petricoin E.F., Zhao W., and Araujo R. P. The amplified peptidome: the new treasure chest of candidate biomarkers // Curr Opin Chem Biol.2006. V. 10(1). P.50−55.
- Beate G., Raila J., Sehouli J., Haebel S., Konsgen D., Mustea A., and Schweigert F.J. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients // BMC cancer. 2005. V.5. P. 133.
- German D.C., Gurnani P., Nandi A., Garner H.R., Fisher W., Diaz-Arrastia R., O’Suilleabhain P., and Rosenblatt K.P. Serum biomarkers for Alzheimer’s disease: proteomic discovery // Biomed Pharmacother. 2007. V.61(7). P.383−389.
- Glojnaric I., Casl M.T., Simic D., and Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma // Clin Chem Lab Med. 2001. V.39(2). P. 129−133.
- Goldman R., Ressom H.W., Abdel-Hamid M., Goldman L., Wang A., Varghese R.S.,
- An Y., et al. Candidate markers for the detection of hepatocellular carcinoma in lowmolecular weight fraction of serum // Carcinogenesis. 2007. V. 28(10). P. 2149−2153.218
- Gomme P.T., McCann K.B., and Bertolini J. Transferrin: structure, function and potential therapeutic actions // Drug Discov Today. 2005. V. 10(4). P. 267−273.
- Gorg A., and Weiss W. 2-D Proteome Analysis Protocols // Methods in Molecular Biology. 1999. V. 112, ed. AJ Link, Totowa, NJ: Humana Press. P. 235−244.
- Greten T.F., Manns M. P., and Korangy F. Myeloid derived suppressor cells in human diseases // International Immunopharmacology. 2011. V. 11(7). P.802−807.
- Gundry R.L. Jelinek C.A., Van Eyk J.E., Fu Q., and Cotter R.J. Investigation of an albumin-enriched fraction of human serum and its albuminome // Proteomics. Clinical Applications. 2007. V. 1. P.73−88.
- Gutfeld O. Expression of Serum Amyloid A, in Normal, Dysplastic, and Neoplastic Human Colonic Mucosa: Implication for a Role in Colonic Tumorigenesis // Journal of Histochemistry and Cytochemistry. 2006. V.54(l). P.63−73.
- Guyon I., Weston J., Barnhill S., and Vapnik V.N. Gene selection for cancer classification using support vector machines // Machine Learning. 2002. V.46. P.389−422.
- Hamacher M., Stephan C., Meyer H.E., and Eisenacher M. Data handling and processing in proteomics // Expert Rev Proteomics. 2009. V.6(3). P. 217−219.
- Havlis J., Thomas H., Sebela M., and Shevchenko A. Fast-response proteomics by accelerated in-gel digestion of proteins // Analytical Chemistry. 2003. V.75(6). P. 13 001 306.
- Heo S.H., Lee S.J., Ryoo H.M., Park J.Y., and Cho J.Y. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS // Proteomics. 2007. V.7(23). P.4292−4302.
- Hiemstra P. S. Novel roles of protease inhibitors in infection and inflammation // Biochem Soc Trans. 2002. V.30(2). P. 116−120.
- Hinerfeld D., Innamorati D., Pirro J., and Tam S.W. Serum/Plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple Mammalian species // Journal of biomolecular techniques. 2004. V. 15(3). P. 184−190.
- Hoagland Luke F.M., Campa M.J., Gottlin E.B., Herndon J.E., and Patz E.F. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer // Cancer. 2007. V. 110(10). P. 2260−2268.
- Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome // Clin Chem. 2006. V.52(7). P. 1223−1237.
- Hortin G.L., Jortani S.A., Ritchie J.C. Jr., Valdes R. Jr., and Chan D.W. Proteomics: a new diagnostic frontier // Clin Chem. 2006. V.52(7). P. 1218−1222.
- Hudis C.A. Trastuzumab—mechanism of action and use in clinical practice // The New England journal of medicine. 2007. V.357(l). P.39−51.
- Ingenbleek Y., and Young V. Transthyretin (prealbumin) in health and disease: nutritional implications // Annu Rev Nutr. 1994. V. 14. P.495−533.
- Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer // Mol Cell Proteomics. 2004. V.3(4). P.355−366.
- Ya J., and Manabe T. Direct targeting of human plasma for matrix-assisted laser desorption/ionization and analysis of plasma proteins by time of flight-mass spectrometry // Electrophoresis. 2005. V. 26(14). P. 2823−2834.
- Kaneti J., Winikoff Y., Zimlichman S., and Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer // Urol Res. 1984. V. 12(5). P. 239−241.
- Karin M. Nuclear factor-kappaB in cancer development and progression // Nature. 2006. V.441(7092). P.431−436.
- Karpova M.A., Moshkovskii S.A., Toropygin I.Y., and Archakov A.I. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives // Journal of proteomics. 2010. V.73(3). P.537−551.
- Kellar K.L., and Iannone M.A. Multiplexed microsphere-based flow cytometric assays // Experimental hematology. 2002. V.30(l 1). P. 1227−1237.
- Kempf W., and Sander C.A. Classification of cutaneous lymphomas an update // Histopathology. 2010. V.56(l). P.57−70.
- Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett. 2006. V. 235(2). P. 159−176.
- Kiernan U.A., Tubbs .K.A, Nedelkov D., Niederkofler E.E., and Nelson R.W. Detection of novel truncated forms of human serum amyloid A protein in human plasma // FEBS letters. 2003. V.537(l-3). P. 166−170.
- Kikuchi S., Honda K., Handa Y., Kato H., Yamashita K., Umaki T., Shitashige M., et al. Serum albumin-associated peptides of patients with uterine endometrial cancer // Cancer Sci. 2007. V.98(6). P.822−829.
- Kobel M., Kalloger S.E., Boyd N., McKinney S., Mehl E., Palmer C., Leung S., et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies // PLoS Med. 2008. V.5(12). P. e232.
- Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases // Mol Immunol. 2001. V.38(2−3). P. 175−187.
- Kos J., Stabuc B., Cimerman N., and Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression // Clin Chem. 1998. V.44(12). P. 2556−2557.
- Kozak K.R., Su F., Whitelegge J. P., Faull K., Reddy S., and Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer // Proteomics. 2005. V.5(17). P.4589−4596.
- Lachmann H.J., Goodman H.J., Gilbertson J.A., Gallimore J.R., Sabin C.A., Gillmore J.D., and Hawkins P.N. Natural history and outcome in systemic AA amyloidosis // The New England journal of medicine. 2007. V.356(23). P. 2361−2371.
- Langley R. G, and Ellis C.N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment // Journal of the American Academy of Dermatology. 2004. V.51(4). P.563−569.
- Lasztity N., Biro L., Nemeth E., Pap A., and Antal M. Protein status in pancreatitis— transthyretin is a sensitive biomarker of malnutrition in acute and chronic pancreatitis // Clin Chem Lab Med. 2002. V.40(12). P. 1320−1324.
- Le L., Chi K., Tyldesley S., Flibotte S., Diamond D.L., Kuzyk M.A., and Sadar M.D. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions // Clin Chem. 2005. V.51(4). P.695−707.
- Lee M.S., Yoo S.A., Cho C.S., Suh P.G., Kim W.U., and Ryu S.H. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis //Journal of immunology. 2007. V. 177(8). P.5585−5594.
- Legrain P., Aebersold R., Archakov A., Bairoch A., Bala K., Beretta L., Bergeron J., et al. 2011. «The human proteome project: current state and future direction // Molecular & cellular proteomics. 2011. V. 10(7).M111.9 993.
- Lenane P., Powell F.C., O’Keane C., Dervan P., O’Sullivan D., Bourke E., and O’Loughlin S. Mycosis fungoides—a review of the management of 28 patients and of the recent literature// International journal of dermatology. 2007. V.46(l). P. 19−26.
- Li J., Orlandi R., White C.N., Rosenzweig J., Zhao J., Seregni E., Morelli D., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry // Clin Chem. 2005. V.51(12). P. 2229−2235.
- Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer // Clin Chem. 2002. V.48(8). P. 1296−1304.
- Liotta L.A., Ferrari M., and Petricoin E. Clinical proteomics: written in blood // Nature. 2003. V.425(6961). P.905.
- Listgarten J., and Emili A. Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry // Mol Cell Proteomics. 2005. V.4(4). P.419−434.
- Lopez M.F., Mikulskis A., Kuzdzal S., Golenko E., Petricoin E.F. 3rd, Liotta L.A.,
- Patton W.F., et al. A novel, high-throughput workflow for discovery and identification of224serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples // Clin Chem. 2007. V.53(6). P. 1067−1074.
- Lopez-Otin C., and Matrisian L.M. Emerging roles of proteases in tumour suppression //Nat Rev Cancer. 2007. V.7(10). P.800−808.
- Lowenthal M.S., Mehta A.I., Frogale K., Bandle R.W., Araujo R. P., Hood B.L., Veenstra T.D., et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients//Clin Chem. 2005. V.51(10). P. 1933−1945.
- Luque-Garcia J.L., and Neubert T.A. Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry // J Chromatogr A. 2007. V. 1153(1−2). P. 259−276.
- Mahlck C.G., and Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma // Gynecol Obstet Invest. 1994. V.37(2). P. 135−140.
- Mahley R.W., Innerarity T.L., Rail S.C. Jr., and Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function // J Lipid Res. 1984. V. 25(12). P. 1277−1294.
- Malik G» Ward M.D., Gupta S.K., Trosset M. W., Grizzle W.E., Adam B.L., Diaz J.I., and Semmes O.J. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer // Clin Cancer Res. 2005. V. 11(3). P. 1073−1085.
- Malle E., Sodin-Semrl S., and Kovacevic A. Serum amyloid A: an acute-phase protein inVved in tumour pathogenesis // Cellular and molecular life sciences. 2009. V.66(l). P.9−26.
- Mann M., Hojrup P., and Roepstorff P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases // Biological mass spectrometry. 1993. V. 22(6). P.338−45.
- Mao Y., Zhou X.B., Pi D.Y., and Sun Y.X. Constructing support vector machine ensembles for cancer classification based on proteomic profiling // Genomics Proteomics Bioinformatics. 2005. V.3(4). P. 238−241.
- Massone .C, Crisman G., Kerl H., and Cerroni L. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality // The British journal of dermatology. 2008. V. 159(4). P.881−886.
- McLerran D., Grizzle W.E., Feng Z., Thompson I.M., Bigbee W.L., Cazares L.H., Chan D.W., et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer // Clin Chem. 2008. V.54(l). P.53−60.
- Morrone G., Corbo L., Turco m.C., Pizzano R., De Felice M., Bridges S, and Venuta S. Transferrin-like autocrine growth factor, derived from T-lymphoma cells, that inhibits normal T-cell proliferation // Cancer Res. 1998. V.48(12). P.3425−3429.
- Mulaomerovic A., Halilbasic A., Cickusic E., Zavasnik-Bergant T., Begic L., andKos J. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma // Cancer Lett. 2007. V. 248(2). P. 192−197.
- Murchison E. P., Tovar C., Hsu A., Bender H.S., Kheradpour P., Rebbeck C.A., Obendorf D., et al. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer // Science. 2010. V.327(5961). P.84−87.
- Nedelkov D., Kiernan U.A., Niederkofler E.E., Tubbs K.A., and Nelson R.W. Investigating diversity in human plasma proteins // Proceedings of the National Academy of Sciences of the United States of America. 2005. V. 102(31). P. 10 852−10 857.
- Nedelkov D., Kiernan U.A., Niederkofler E.E., Tubbs K.A., Nelson R.W. Population proteomics: the concept, attributes, and potential for cancer biomarker research // Molecular &Cellular Proteomics. 2006. V.5(10). P. 1811−1888.
- Nilsson T., Mann M., Aebersold R., Yates J.R., Bairoch A., and Bergeron J.J. Mass spectrometry in high-throughput proteomics: ready for the big time // Nature methods. 2010. V.7(9). P.681−685.
- Omenn G.S. Strategies for plasma proteomic profiling of cancers // Proteomics. 2006. V.6(20). P.5662−5673.
- Palha J.A. Transthyretin as a thyroid hormone carrier: function revisited // Clin Chem Lab Med. 2002. V.40(12). P. 1292−1300.
- Paret C., Schon Z., Szponar A., and Kovacs G. Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome // European urology. 2010. V.57(5). P.859−866.
- Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., et al. Use of proteomic patterns in serum to identify ovarian cancer // Lancet.2002. V.359(9306). P.572−577.
- Petricoin E.F., Belluco C., Araujo R. P., and Liotta L.A. The blood peptidome: a higher dimension of information content for cancer biomarker discovery // Nat Rev Cancer. 2006. V.6(12). P.961−967.
- Petricoin E.F., and Liotta L.A. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer // Curr Opin Biotechnol. 2004. V. 15(1). P. 2430.
- Pimpinelli N., Olsen E.A., Santucci M., Vonderheid E., Haeffner A.C., Stevens S., Burg G., et al. Defining early mycosis fungoides // Journal of the American Academy of Dermatology. 2005. V.53(6). P. 1053−1063.
- Raguso C.A., Dupertuis Y.M., and Pichard C. The role of visceral proteins in the nutritional assessment of intensive care unit patients // Curr Opin Clin Nutr Metab Care.2003. V.6(2). P. 211−216.
- Rai A J., Zhang Z., Rosenzweig J., Shih Ie.M., Pham T., Fung E.T., Sokoll L.J., and Chan D.W. Proteomic approaches to tumor marker discovery // Arch Pathol Lab Med. 2002. V. 126(12). P. 1518−1526.
- Rakoff-Nahoum S. Why cancer and inflammation? // Yale J Biol Med. 2006. V.79(3−4). P. 123−130.
- Ramankulov A., Lein M., Johannsen M., Schrader M., Miller K., Loening S.A., and Jung K. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma // Cancer letters. 2008. V. 269(1). P.85−92.
- Regnier F.E., Skates S.J., Mesri M., Rodriguez H., Tezak Z., Kondratovich M. V., Alterman M.A., et al. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration // Clinical chemistry. 2010. V.56(2). P. 165−171.
- Rosen J.M., and Jordan C.T. The increasing complexity of the cancer stem cell paradigm // Science. 2009. V.324(5935). P. 1670−1673.
- Rosenthal C.J., and Sullivan L.M. Serum amyloid A to monitor cancer dissemination // Annals of internal medicine. 1979. V.91(3). P.383−390.
- Roth M.J., Parks B.A., Ferguson J.T., Boyne M.T., and Kelleher N.L. 'Proteotyping': population proteomics of human leukocytes using top down mass spectrometry // Analytical chemistry. 2008. V.80(8) (April 15). P. 2857.
- Scigelova M., Hornshaw ML, Giannakopulos A., and Makarov A. Fourier transform mass spectrometry // Molecular & cellular proteomics. 2011. V. 10(7). Mill.9 431.
- Scigelova M., and Makarov A. Orbitrap mass analyzer—overview and applications in proteomics // Proteomics. 2006. V.6 Suppl 2. P. 16−21.
- Selevsek N., Matondo M., Sanchez Carbayo M., Aebersold R., and Domon B. Systematic quantification of peptides/proteins in urine using selected reaction monitoring // Proteomics. 2011. V. 11(6). P. 1135−1147.
- Simpson R.J., Bernhard O.K., Greening D.W., and Moritz R.L. Proteomics-driven cancer biomarker discovery: looking to the future // Curr. Opin. Chem. Biol. 2008. V. 12(1). P.72−77.
- Sorace J.M., and Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling // BMC bioinformatics. 2003. V.4. P. 24.
- Srinivas P.R., Srivastava S., Hanash S., and Wright G.L. Proteomics in early detection of cancer// Clinical chemistry. 2001. V.47(10). P. 1901−1911.
- Steel L.F., Trotter M.G., Nakajima P.B., Mattu T.S., Gonye G., and Block T. Efficient and specific removal of albumin from human serum samples // Molecular & cellular proteomics. 2003. V. 2(4). P. 262−270.
- Stephens P.J., McBride D.J., Lin M.L., Varela I., Pleasance E.D., Simpson J.T., Stebbings L.A., et al. Complex landscapes of somatic rearrangement in human breast cancer genomes //Nature. 2009. V.462(7276). P. 1005−1010.
- Stratton M.R., Campbell P.J., and Futreal P.A. The cancer genome // Nature. 2009. V.458(7239). P.719−724.
- Subramanian J., and Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? // J. Natl. Cancer Inst. 2010. V. 102(7). P.464−474.
- Sun Z., and Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression // Lancet Oncol. 2004. V. 5(3). P. 182 190.
- Tamir S., Kadner S.S., Katz J., and Finlay T.H. Regulation of antitrypsin and antichymotrypsin synthesis by MCF-7 breast cancer cell sublines // Endocrinology. 1990. V. 127(3). P. 1319−1328.
- Tan A.C., Naiman D.Q., Xu L., Winslow R.L., and Geman D. Simple decision rules for classifying human cancers from gene expression profiles // Bioinformatics (Oxford, England). 2005. V. 21(20). P.3896−3904.
- Timms J.F., Arslan-Low E., Gentry-Maharaj A., Luo Z., T’Jampens D., Podust V.N., Ford J., et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles // Clin. Chem. 2007. V.53(4). P.645−656.
- Tirumalai R.S., Chan K.C., Prieto D.A., Issaq H.J., Conrads T. P., and Veenstra T.D. Characterization of the low molecular weight human serum proteome // Mol. Cell. Proteomics. 2003. V. 2(10). P. 1096−1103.
- Tran J.C., Zamdborg L., Ahlf D.R., Lee J.E., Catherman A.D., Durbin K.R., Tipton J.D., et al. Mapping intact protein isoforms in discovery mode using top-down proteomics //Nature. 2011. V.480(7376). P. 254−258.
- Uhlar C.M., and Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant // Eur J Biochem. 1999. V. 265(2). P.501−523.
- Vapnik V., and Chapelle O. Bounds on error expectation for support vector machines //Neural computation. 2000. V. 12(9). P. 2013−2036.
- Villanueva J., Nazarian A., Lawlor K., Yi S.S., Robbins R.J., and Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for 'functional' biomarker discovery // Mol. Cell. Proteomics. 2008. V.7(3). P.509−518.
- Villanueva J., Philip J., DeNoyer L., and Tempst P. Data analysis of assorted serum peptidome profiles // Nat. Protoc. 2007. V. 2(3). P.588−602.
- Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., 01shen A.B., Fleisher M., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns // J. Clin. Invest. 2006. V. 116(1). P. 271−284.
- Vlahou A., Schorge J.O., Gregory B.W., and Coleman R.L. Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data // J. Biomed. Biotechnol. 2003. V. 2003(5). P.308−314.
- Vlasova M. A., andMoshkovskii S.A. Molecular interactions of acute phase serum amyloid A: Possible inVvement in carcinogenesis // Biochemistry (Moscow). 2006. V.71(10) (October). P. 1051−1059.
- Van Vlierberghe H., Langlois M., and Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease // Clin. Chim. Acta. 2004. V.345(l-2). P.35−42.
- Vostrejs M., Moran P.L., and Seligman P.A. Transferrin synthesis by small cell lung cancer cells acts as an autocrine regulator of cellular proliferation // J. Clin. Invest. 1988. V.82(l). P.331−339.
- Wagner M., Naik D., and Pothen A. Protocols for disease classification from mass spectrometry data // Proteomics. 2003. V.3(9). P. 1692−1698.
- Walker J.M. The bicinchoninic acid (BCA) assay for protein quantitation // Methods in molecular biology. 1994. V.32. P.5−8.
- Ward D.G., Suggett N., Cheng Y" Wei W., Johnson H., Billingham L.J., Ismail T., Wakelam M.J., Johnson P.J., and Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis // Br. J. Cancer. 2006. V.94(12). P. 1898−1905.
- Washburn M. P., Wolters D., and Yates J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology // Nature biotechnology. 2001. V. 19(3). P. 242−247.
- Wassell J. Haptoglobin: function and polymorphism // Clin Lab. 2000. V.46(ll-12). P.547−552.
- Wei Y.S., Zheng Y.H., Liang W.B., Zhang J.Z., Yang Z.H., Lv M.L., Jia J., and Zhang L. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis // Cancer. 2008. V. 112(3). P.544−551.
- Whelan L.C., Power K.A., McDowell D.T., Kennedy J., and Gallagher W.M. Applications of SELDI-MS technology in oncology // J. Cell. Mol. Med. 2008. V. 12(5A). P. 1535−1547.
- Whiteaker J.R., Zhang H., Eng J.K., Fang R., Piening B.D., Feng L. C, Lorentzen T.D., et al. Head-to-head comparison of serum fractionation techniques // J. Proteome Res. 2007. V.6(2). P.828−836.
- Whiteley G.R., Colantonio S., Sacconi A., and Saul R.G. Analytical considerations for mass spectrometry profiling in serum biomarker discovery // Clin. Lab. Med. 2009. V. 29(1). P.57−69.
- Xu L., Tan A.C., Naiman D.Q., Geman D., and Winslow R.L. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data // Bioinformatics. 2005. V. 21(20). P.3905−3911.
- Yavelow .J, Tuccillo A., Kadner S.S., Katz J., and Finlay T.H. Alpha 1-antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells // J. Clin. Endocrinol. Metab. 1997. V.82(3). P.745−752.
- Yildiz P.B., Shyr Y., Rahman J.S., Wardwell N.R., Zimmerman L.J., Shakhtour B., Gray W.H., et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer // J Thorac Oncol. 2007. V. 2(10). P.893−901.
- Yurkovetsky Z., Skates S., Lomakin A., Nolen B., Pulsipher T., Modugno F., Marks J., et al. Development of a Multimarker Assay for Early Detection of Ovarian Cancer // J Clin Oncol. 2010. V. 28(13). P. 2159−2166.
- Zackheim H.S., and McCalmont T.H. Mycosis fungoides: the great imitator // Journal of the American Academy of Dermatology. 2002. V.47(6). P.914−918.
- Zhang L., Yu W., He T., Yu J., Caffrey R.E., Dalmasso E.A., Fu S., et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor// Science. 2002. V. 298(5595). P.995−1000.
- Zhang X., Lu X., Shi Q., Xu X.Q., Leung H.C., Harris L.N., Iglehart J.D., Miron A., Liu J.S., and Wong W.H. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data // BMC Bioinformatics. 2006. V.7. P. 197.
- Zhang Z" Bast R.C. Jr., Yu Y., Li J., Sokoll L.J., Rai A.J., Rosenzweig J.M., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer // Cancer Res. 2004. V.64(16). P.5882−5890.
- Zhou M., Lucas D.A., Chan K.C., Issaq H.J., Petricoin E.F. 3rd, Liotta L.A., T.D. Veenstra, and Conrads T. P. An investigation into the human serum 'interactome' //
- Electrophoresis. 2004. V. 25(9). P. 1289−1298.236
- Zhu W., Wang X., Ma Y., Rao M., Glimm J., andKovach J.S.Detection of cancer-specific markers amid massive mass spectral data// Proc. Natl. Acad. Sci. USA. 2003. V. 100(25). P. 14 666−14 671.
- Zimmer J.S., Monroe M.E., Qian W.J., and Smith R.D. Advances in proteomics data analysis and display using an accurate mass and time tag approach // Mass Spectrom Rev. 2006. V. 25(3). P.450−482.
- Zinkin N.T., Grail F., Bhaskar K., Out H.H., Spentzos D., Kalmowitz B., Wells M., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease // Clin Cancer Res. 2008. V. 14(2). P.470−477.
- Zolotarjova N., Martosella J., Nicol G., Bailey J., Boyes B.E., and Barrett W.C. Differences among techniques for high-abundant protein depletion // Proteomics. 2005. V.5(13). P.3304−3313.
- Zweig M.H., and Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine // Clinical chemistry. 1993. V.39(4). P.561−577.1. БЛАГОДАРНОСТИ
- Хочу посвятить свой скромный вклад в науку памяти академика РАМН М. Д. Машковского, с которым мне посчастливилось общаться в первые годы выполнения работы.